Ocular Therapeutix plans $32.5m public offering to fund NDA resubmission for Dextenza

Updated to include the offering’s pricing information. Ocular Therapeutix (NSDQ:OCUL) said today that it plans to launch an underwritten public offering of 6.5 million shares of common stock at $5.00 apiece to help fund the resubmission of its new drug application for Dextenza, an ocular post-surgical pain-relief implant that was rejected by the FDA last year. The Bedford, Mass.-based company said it will also offer underwriters a 30-day option to buy an additional 15% of the shares in the offering on the same terms. Get the full story at our sister site, Drug Delivery Business News. The post Ocular Therapeutix plans $32.5m public offering to fund NDA resubmission for Dextenza appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Funding Roundup Optical/Ophthalmic Pain Management Pharmaceuticals Regulatory/Compliance Surgical Wall Street Beat oculartherapeutix Source Type: news